INFECTIONS OF THE IMMUNOCOMPROMISED HOST: Edited by Barbara D. Alexander and Rachel A. MillerBacteriophage therapy as a treatment option for transplant infectionsAslam, SaimaAuthor Information Division of Infectious Diseases and Global Public Health, Center for Innovative Phage Applications and Therapeutics, University of California, San Diego, USA Correspondence to Saima Aslam, MD, MS, 4510 Executive Drive, MC 7745, San Diego, CA 92121, USA. E-mail: firstname.lastname@example.org; Twitter: @DocSaimaAslam Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Website (www.co-infectiousdiseases.com). Current Opinion in Infectious Diseases: August 2020 - Volume 33 - Issue 4 - p 298-303 doi: 10.1097/QCO.0000000000000658 Buy SDC Metrics Abstract Purpose of review Since initial description of the successful use of intravenous bacteriophage therapy in the United States in 2017, there is widespread interest in using bacteriophage therapy for multidrug-resistant (MDR) infections. Recent findings Recent published cases of bacteriophage therapy in transplant candidates and recipients are reviewed highlighting its safety and potential efficacy when used as an adjunct to systemic antibiotics for a variety of clinical indications. An overview of access to bacteriophage therapy in the United States is also provided. Summary The reviewed cases form the basis for ongoing compassionate use of bacteriophage therapy in transplant candidates and recipients with life-threatening MDR infections until data from clinical trials are available to guide therapy. Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.